Pluri (NASDAQ:PLUR) Issues Earnings Results

Pluri (NASDAQ:PLUR) released its earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, Zacks reports.

Pluri Price Performance

Shares of PLUR stock traded down $0.19 during midday trading on Thursday, reaching $3.55. 16,305 shares of the company traded hands, compared to its average volume of 11,817. The firm’s 50 day simple moving average is $3.24 and its two-hundred day simple moving average is $4.02. The firm has a market cap of $35.43 million, a PE ratio of -0.75 and a beta of 0.67. Pluri has a 1-year low of $2.82 and a 1-year high of $7.13.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Hedge Funds Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.